TY - JOUR
T1 - Early decrease in intermediate monocytes in peripheral blood is characteristic of multiple system atrophy-cerebellar type
AU - Matsuse, Dai
AU - Yamasaki, Ryo
AU - Maimaitijiang, Guzailiayi
AU - Yamaguchi, Hiroo
AU - Masaki, Katsuhisa
AU - Isobe, Noriko
AU - Matsushita, Takuya
AU - Kira, Jun ichi
N1 - Funding Information:
This study was supported by Health and Labour Sciences Research Grants on Comprehensive Research on Disability, Health and Welfare, Japan (H29 Nanchi-Ippan-0009). The authors thank the patients for their participation. We also thank Edanz Group ( www.edanzediting.com/ac ) for editing a draft of this manuscript.
Funding Information:
This study was supported by grants from JSPS KAKENHI , Grant Nos. 18K07501 (DM), 19K07963 (RY), 19H01045 (JK), and 19H05562 (JK), and by Health and Labour Sciences Research Grants on Comprehensive Research on Disability Health and Welfare, Japan (H29 Nanchi-Ippan-009).
Funding Information:
RY received grants and personal fees from the Japan Society for the Promotion of Science, Biogen Japan, and the Japan Blood Products Organization. NI received grant support from Mitsubishi Tanabe Pharma , the Osoegawa Neurology Clinic, Bayer Yakuhin Ltd. and the Japan Blood Products Organization. TM received speech honoraria payments from Biogen Japan, the Takeda Pharmaceutical Company. JK received grants and personal fees from Biogen Japan, Bayer Healthcare, Novartis Pharma, Mitsubishi Tanabe Pharma, Eisai, Sanofi, Nobelpharma, Otsuka Pharmaceutical, the Chugai Pharmaceutical Company, and Teijin Pharma. We report no other disclosures. DM, KM, GM, and HY have nothing to declare.
Funding Information:
This study was supported by Health and Labour Sciences Research Grants on Comprehensive Research on Disability, Health and Welfare, Japan (H29 Nanchi-Ippan-0009). The authors thank the patients for their participation. We also thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. This study was supported by grants from JSPS KAKENHI, Grant Nos. 18K07501 (DM), 19K07963 (RY), 19H01045 (JK), and 19H05562 (JK), and by Health and Labour Sciences Research Grants on Comprehensive Research on Disability Health and Welfare, Japan (H29 Nanchi-Ippan-009). RY received grants and personal fees from the Japan Society for the Promotion of Science, Biogen Japan, and the Japan Blood Products Organization. NI received grant support from Mitsubishi Tanabe Pharma, the Osoegawa Neurology Clinic, Bayer Yakuhin Ltd. and the Japan Blood Products Organization. TM received speech honoraria payments from Biogen Japan, the Takeda Pharmaceutical Company. JK received grants and personal fees from Biogen Japan, Bayer Healthcare, Novartis Pharma, Mitsubishi Tanabe Pharma, Eisai, Sanofi, Nobelpharma, Otsuka Pharmaceutical, the Chugai Pharmaceutical Company, and Teijin Pharma. We report no other disclosures. DM, KM, GM, and HY have nothing to declare.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/12/15
Y1 - 2020/12/15
N2 - To identify biomarkers for multiple system atrophy-cerebellar type (MSA-C), we used flow cytometry to measure surface marker expression of peripheral blood monocytes from patients with MSA-C or hereditary spinocerebellar degeneration (hSCD) and from healthy controls (HCs). The percentage of intermediate monocytes was significantly lower in MSA-C patients than in hSCD patients and HCs and showed significant positive correlations with disease duration and unified MSA rating scale scores. The percentage of CD62L+ intermediate monocytes was significantly lower in MSA-C patients than in hSCD patients and HCs. Early decrease of peripheral blood intermediate monocytes is characteristic of MSA-C and is a biomarker.
AB - To identify biomarkers for multiple system atrophy-cerebellar type (MSA-C), we used flow cytometry to measure surface marker expression of peripheral blood monocytes from patients with MSA-C or hereditary spinocerebellar degeneration (hSCD) and from healthy controls (HCs). The percentage of intermediate monocytes was significantly lower in MSA-C patients than in hSCD patients and HCs and showed significant positive correlations with disease duration and unified MSA rating scale scores. The percentage of CD62L+ intermediate monocytes was significantly lower in MSA-C patients than in hSCD patients and HCs. Early decrease of peripheral blood intermediate monocytes is characteristic of MSA-C and is a biomarker.
UR - http://www.scopus.com/inward/record.url?scp=85091257817&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091257817&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2020.577395
DO - 10.1016/j.jneuroim.2020.577395
M3 - Article
C2 - 32977251
AN - SCOPUS:85091257817
VL - 349
JO - Advances in Neuroimmunology
JF - Advances in Neuroimmunology
SN - 0165-5728
M1 - 577395
ER -